Medline Reports Third Quarter and Nine Months 2026 Results

Medline posts strong sales and EBITDA growth but faces sharp net income decline.

What the company is saying

Medline Inc. reports double-digit net sales growth for both the third quarter and first nine months of 2026, with CEO Jim Boyle highlighting continued momentum, commercial execution, and strategic progress in capacity and technology. The company frames its narrative around robust revenue expansion—10.4% year-over-year for the quarter and 10.9% for the nine months—while acknowledging headwinds from increased inventory costs, higher operating expenses, and a significant fire loss. Management attributes the 1.2% quarterly and 28.8% nine-month net income declines primarily to inflation, customer mix, and the $316 million Tracy, California distribution center fire. The announcement emphasizes capital allocation discipline, with a new $1 billion share repurchase authorization and a $750 million prepayment on the 2033 Refinancing Term Loan Facility. Medline raises its full-year 2026 organic sales growth outlook to 10.0–10.5% and reaffirms Adjusted EBITDA guidance of $3.3–$3.4 billion, explicitly excluding $324 million in IEEPA tariff refunds from EBITDA guidance. The tone is confident but measured, with operational and financial challenges presented transparently alongside positive sales and cash flow trends.

What the data suggests

Third quarter 2026 net sales rose 10.4% to $7.9 billion, with organic sales up 10.5%, but net income slipped 1.2% to $318 million due to inflation, higher expenses, and customer mix. Adjusted EBITDA for the quarter increased 11.8% to $960 million. For the nine months, net sales climbed 10.9% to $22.9 billion, but net income dropped 28.8% to $696 million, impacted by a $316 million fire loss, higher costs of goods sold, and segment mix. Adjusted EBITDA for the nine months rose 5.0% to $2.8 billion. Diluted EPS for the quarter and nine months were $0.22 and $0.45, while Adjusted Diluted EPS were $0.44 and $1.27, respectively. Operating cash flow for the nine months was $2.2 billion, with free cash flow at $1.8 billion after $348 million in capital expenditures. The company recognized $81 million and $324 million in net IEEPA tariff refund benefits for the quarter and nine months, respectively, with $70 million and $402 million in tariff refunds reducing cost of goods sold. The $1 billion share repurchase and $750 million debt prepayment signal strong cash generation. The company’s raised organic sales growth outlook and reaffirmed Adjusted EBITDA guidance are supported by realised sales and EBITDA growth, though profitability remains pressured by exceptional costs.

Analysis

The announcement is largely factual, with detailed disclosure of realised financial and operational results for both the quarter and year-to-date. Key metrics such as net sales, organic sales, net income, Adjusted EBITDA, cash flow, and capital expenditures are all quantified and compared to prior periods. While the company uses some positive language about advancing strategic priorities and long-term growth, these statements are generic and not materially exaggerated relative to the evidence. The only forward-looking elements are the raised full-year outlooks for organic sales and Adjusted EBITDA, which are standard in quarterly reporting and are supported by recent realised performance. There is no evidence of narrative inflation or overstatement: the tone is measured, and the company is transparent about both positive (sales, EBITDA, cash flow) and negative (net income decline, fire loss, higher costs) developments. Capital allocation actions (share repurchase, debt prepayment) are disclosed as completed or authorised, not merely planned. The gap between narrative and evidence is minimal.

Risk flags

• ●Profitability risk remains elevated as net income declined 28.8% year-over-year for the nine months, despite strong sales and EBITDA growth. This was driven by a combination of inflation, higher operating expenses, and a $316 million fire loss, indicating that cost pressures and one-off events can materially impact bottom-line results.
• ●Operational risk is highlighted by the fire at the Tracy, California distribution center, which resulted in $316 million in net losses. This event underscores the vulnerability of Medline’s distribution network to physical disruptions and the potential for significant financial impact from unforeseen incidents.
• ●Customer and segment mix contributed to both higher costs and lower net income, suggesting that shifts in business composition or customer base could continue to affect margins and profitability. This risk is compounded by ongoing inflation and tariff-related cost volatility.
• ●Capital allocation risk is present as the company embarks on a $1 billion share repurchase program and significant debt prepayment. While these actions reflect strong cash flow, they reduce available liquidity and may limit flexibility if further operational disruptions or cost spikes occur.
• ●The exclusion of $324 million in IEEPA tariff refunds from Adjusted EBITDA guidance introduces complexity to earnings comparability and may obscure underlying operational performance, especially if further tariff-related adjustments arise.

Bottom line

Medline’s third quarter and year-to-date results show robust top-line and EBITDA growth, but net income is under significant pressure from cost inflation, higher operating expenses, and a major distribution center fire. The company’s strong cash generation has enabled a $1 billion share repurchase authorization and a $750 million debt prepayment, signaling confidence in its financial position. The raised organic sales growth outlook and reaffirmed Adjusted EBITDA guidance for 2026 are credible given the near-term timeline and recent performance, though profitability remains a concern. The impact of exceptional items like the Tracy fire and IEEPA tariff refunds complicates earnings quality and comparability. Investors should focus on whether Medline can translate sales and EBITDA momentum into sustainable net income growth and margin recovery. The most important takeaway is that while the business is expanding and generating cash, cost control and operational resilience are critical to restoring earnings power.

Announcement summary

(NASDAQ:MDLN) Medline Inc. reported its operating results for the three and nine months ended September 26, 2026. Third quarter 2026 net sales increased 10.4% to $7.9 billion, compared to $7.1 billion in the third quarter 2025, with Organic Sales increasing 10.5%. Third quarter 2026 net income decreased 1.2% to $318 million, compared to $322 million in the third quarter 2025, primarily due to increased inventory costs from inflation, higher operating expenses, and customer mix, partially offset by higher net sales and net IEEPA tariff refund benefits. Third quarter 2026 Adjusted EBITDA increased 11.8% to $960 million, compared to $859 million in the third quarter 2025. Third quarter 2026 diluted earnings per share and Adjusted Diluted EPS were $0.22 and $0.44, respectively. For the nine months ended September 26, 2026, net sales increased 10.9% to $22.9 billion, compared to $20.6 billion in the 2025 period, with Organic Sales increasing 10.7%. Nine months 2026 net income decreased 28.8% to $696 million, compared to $977 million in the first nine months of 2025, primarily due to higher operating expenses, net losses of $316 million related to the fire at the Tracy, California distribution center, higher cost of goods sold including tariffs, customer and segment mix, and increased inventory costs from inflation, partially offset by higher net sales and net IEEPA tariff refund benefits. Nine months 2026 Adjusted EBITDA increased 5.0% to $2.8 billion, compared to $2.7 billion in the nine months 2025. Nine months 2026 diluted earnings per share and Adjusted Diluted EPS were $0.45 and $1.27, respectively. Net cash provided by operating activities for the first nine months of 2026 was $2.2 billion, and Free Cash Flow was $1.8 billion, partially offset by $348 million of capital expenditures, mainly for automation, new distribution centers, and kitting manufacturing capacity expansion. In October, the Board approved a share repurchase program authorizing up to $1 billion of Class A common stock and/or units of Medline Holdings, LP, and the company prepaid $750 million in aggregate principal amount of the 2033 Refinancing Term Loan Facility. The company raised its full year 2026 outlook for Organic Sales growth to 10.0% to 10.5%, up from 9.0% to 10.0%, and reaffirmed its Adjusted EBITDA outlook of $3.3 billion to $3.4 billion. The Adjusted EBITDA outlook excludes $324 million of net tariff refunds through the first nine months of 2026. Following the U.S. Supreme Court’s February 2026 ruling that IEEPA tariffs were unauthorized, the company recognized $81 million and $324 million of net IEEPA tariff refund benefits during the three and nine months ended September 26, 2026, respectively. These amounts reflect tariff refunds of $70 million and $402 million, respectively, recorded as a reduction of cost of goods sold. For the three month period, the net benefit also included an $11 million increase in net sales related to an adjustment of customer repayment amounts. For the nine month period, the net benefit was partially offset by a $78 million reduction in net sales related to accrued customer repayments associated with IEEPA tariff refunds. All these amounts were recorded within the Medline Brand segment and included in net income and Adjusted EBITDA. The company will host a live conference call and Q&A session with investors and analysts on November 4, 2026, at 8:30 a.m. CT / 9:30 a.m. ET to discuss its third quarter and nine months 2026 earnings results.

Disagree with this article?